Literature DB >> 20512072

Tissue banking of diagnostic lung cancer biopsies for extraction of high quality RNA.

Malcolm H Lawson1, Doris M Rassl, Natalie M Cummings, Roslin Russell, Jaymin B Morjaria, James D Brenton, Gillian Murphy, Robert C Rintoul.   

Abstract

INTRODUCTION: There is a clear need to develop a practical approach to obtain high quality RNA for gene expression analysis from lung cancer patients. Current approaches are restricted to using material from surgical resection specimens. We systematically investigated whether high quality RNA could be obtained from routine lung cancer diagnostic biopsies to determine the optimum method.
METHODS: Extra biopsies were taken at diagnosis from patients later confirmed to have lung cancer. Comparisons were made between RNA extracted from samples snap frozen in liquid nitrogen and those treated with an RNA preservative before freezing. Further comparisons were made between biopsies taken by different methods.
RESULTS: Acceptable RNA for gene expression analysis was extracted from 72% of lung cancer biopsies. Use of an RNA preservative for storage allowed the extraction of higher quality, more intact RNA from biopsies gathered by both endobronchial forceps and transbronchial needle aspiration. High quality RNA could also be extracted from computed tomography-guided needle core biopsies.
CONCLUSION: Banking lung cancer biopsy specimens by storage in an RNA preservative solution will allow use of a broader spectrum of lung cancers for gene expression analysis. We describe a model that makes personalized medicine for lung cancer patients a more practical proposition.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20512072     DOI: 10.1097/JTO.0b013e3181ddbbe9

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  10 in total

Review 1.  Quality assurance of RNA expression profiling in clinical laboratories.

Authors:  Weihua Tang; Zhiyuan Hu; Hind Muallem; Margaret L Gulley
Journal:  J Mol Diagn       Date:  2011-10-20       Impact factor: 5.568

2.  Turning the tide in lung cancer.

Authors:  Malorye Allison
Journal:  Nat Biotechnol       Date:  2010-10       Impact factor: 54.908

Review 3.  Biobanking in genomic medicine.

Authors:  Jane H Zhou; Aysegul A Sahin; Jeffrey N Myers
Journal:  Arch Pathol Lab Med       Date:  2015-06       Impact factor: 5.534

Review 4.  From tissue to molecular phenotyping: pre-analytical requirements heidelberg experience.

Authors:  Thomas R Muley; Felix Jf Herth; Philipp A Schnabel; Hendrik Dienemann; Michael Meister
Journal:  Transl Lung Cancer Res       Date:  2012-06

5.  Tumor acquisition for biomarker research in lung cancer.

Authors:  Marvaretta Stevenson; Jared Christensen; Debra Shoemaker; Traci Foster; William T Barry; Betty C Tong; Momen Wahidi; Scott Shofer; Michael Datto; Geoffrey Ginsburg; Jeffrey Crawford; Thomas D'Amico; Neal Ready
Journal:  Cancer Invest       Date:  2014-05-09       Impact factor: 2.176

6.  Strategies for biochemical and pathologic quality assurance in a large multi-institutional biorepository; The experience of the PROCURE Quebec Prostate Cancer Biobank.

Authors:  Fadi Brimo; Armen Aprikian; Mathieu Latour; Bernard Têtu; Alexandre Doueik; Eleonora Scarlata; Lucie Hamel; Ginette McKercher; Fred Saad; Louis Lacombe; Michel Carmel; Simone Chevalier
Journal:  Biopreserv Biobank       Date:  2013-10       Impact factor: 2.300

7.  Pre-Analytical Determination of the Effect of Extended Warm or Cold Ischaemia on RNA Stability in the Human Ileum Mucosa.

Authors:  Serene M L Lee; Celine Schelcher; Reinhard Thasler; Tobias S Schiergens; Wolfgang E Thasler
Journal:  PLoS One       Date:  2015-09-15       Impact factor: 3.240

8.  EBUS-TBNA provides highest RNA yield for multiple biomarker testing from routinely obtained small biopsies in non-small cell lung cancer patients - a comparative study of three different minimal invasive sampling methods.

Authors:  Gerald Schmid-Bindert; Yongsheng Wang; Hongbin Jiang; Hui Sun; Thomas Henzler; Hao Wang; Lothar R Pilz; Shengxiang Ren; Caicun Zhou
Journal:  PLoS One       Date:  2013-10-29       Impact factor: 3.240

9.  Efficient utilization of EBUS-TBNA samples for both diagnosis and molecular analyses.

Authors:  F Oezkan; Am Khan; P Zarogoulidis; W Hohenforst-Schmidt; D Theegarten; K Yasufuku; T Nakajima; L Freitag; K Darwiche
Journal:  Onco Targets Ther       Date:  2014-11-10       Impact factor: 4.147

10.  Clinical implementation of RNA signatures for pharmacogenomic decision-making.

Authors:  Weihua Tang; Zhiyuan Hu; Hind Muallem; Margaret L Gulley
Journal:  Pharmgenomics Pers Med       Date:  2011-09-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.